证券代码：688315 证券简称：诺禾致源 公告编号：2024-025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总股本 1%暨 回购进展公告 重要内容提示： | 回购方案首次披露日 | 2024/2/6，由实际控制人、董事长兼总经理李瑞强 | | --- | --- | | | 提议 | | 回购方案实施期限 | 2024 年 2 月 5 日第三届董事会第十五次会议审议 | | | 通过后 12 个月 | | 预计回购金额 | 8,000 万元~16,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 5,813,109 股 | | 累计已回购股数占总股本比 | 1.40% | | 例 | | | 累计已回购金额 | 万元 8,143.05 | | 实际回购价格区间 | 12.77 元/股~15.86 元/股 | ...

| --- | --- | --- | --- | --- | --- | --- | |-------|----------------------------------------|--------|-------|-------|-------|-------| | | [T 重 a 要 bl 财 e 务 _P 指 r 标 ofit] | 2022A | 2023A | 2024E | 2025E | 2026E | | | 营业总收入 (百万元) | 1,926 | 2,002 | 2,413 | 2,959 | 3,675 | | | 增长率 YoY % | 3.2% | 4.0% | 20.5% | 22.6% | 24.2% | | | 归属母公司净利润 ( 百万元 ) | 177 | 178 | 221 | 280 | 356 | | | 增长率 YoY% | -21.3% | 0.5% | 24.3% | 26.5% | 27.0% | | | 毛利率 % | 44.3% | 42.7% | 42.6% | 42.7% | 42.7% | | | 净资产收益率 ROE% | 9.0% | ...

经营稳中向好，全球化服务能力持续提升 诺禾致源公布 2023 年度报告。2023 年公司实现营业收入 20.02 亿元（同 比增长 3.97%）；实现归母净利润 1.78 亿元（同比增长 0.47%）；实现扣 非后归母净利润 1.40 亿元（同比下滑 8.92%）。 诺禾致源公布 2024 年度一季报。2024Q1 公司实现营业收入 4.68 亿元（同 比增长 6.32%）；实现归母净利润 2732 万元（同比增长 21.40%）；实现 扣非后归母净利润 2128 万元（同比增长 6.85%）。 全球本地化战略深入布局，海外业务稳健增长。2023 年大陆收入 10.12 亿 元（同比下滑 9.43%），港澳台及海外收入 9.85 亿元（同比增长 22.06%）。 公司业务覆盖 90 多个国家和地区，随着德国、日本实验室陆续启用，全球 区域服务能力持续加强。公司服务客户近 7300 家，全球学术研究机构 TOP100、全球药企营收 TOP10 已实现全覆盖，全球市场竞争优势持续巩固。 盈利预测与投资建议。考虑全球宏观环境影响，我们预计 2024-2026 年公 司营收分别为 23.15、26.94、31.54 ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 2023年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京诺禾致源 科技股份有限公司（以下简称"诺禾致源"或"公司"）首次公开发行并在科创板上市及 2022年向特定对象发行股票的持续督导保荐机构，根据《证券发行上市保荐业务管理 办法》、《上海证券交易所股票上市规则（2023 年 2 月修订）》、《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》、《上海证 券交易所上市公司自律监管指引第 11号——持续督导》 等相关法规和规范性文件的要 求，对诺禾致源2023年度募集资金的存放和使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 1、2021年首次公开发行股票 经中国证券监督管理委员会《关于同意北京诺禾致源科技股份有限公司首次公开 发行股票注册的批复》（证监许可【2021】737号）同意，北京诺禾致源科技股份有限 公司（以下简称"公司"）已发行人民币普通股40,200,000.00股，每股发行价格12.76元， ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 预计 2024 年日常关联交易的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京 诺禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）首次公开发行 并在科创板上市及 2022 年向特定对象发行股票的持续督导保荐机构，根据《证 券发行上市保荐业务管理办法》、《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求（2022 年修订）》、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》、《上海证券交易所科创板股票上市规则（2020 年 12 月修订）》，对诺禾致源关于预计 2024 年日常关联交易的议案的事项进行了 审慎核查，核查情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、董事会表决情况和关联董事回避情况 2024 年 4 月 12 日，北京诺禾致源科技股份有限公司（以下简称"公司"） 第三届董事会第十六次会议审议通过《关于预计 2024 年日常关联交易的议案》， 其中《与天津食安居餐饮管理有限公司的关联交易》关联董事李瑞强先生回避表 决，4 位非关联董事全部 ...

1 中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京 诺禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）首次公开发行 并在科创板上市及 2022 年向特定对象发行股票的持续督导保荐机构，根据《证 券发行上市保荐业务管理办法》、《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求（2022 年修订）》、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》、《上海证券交易所科创板股票上市规则（2020 年 12 月修订）》，对诺禾致源使用暂时闲置募集资金进行现金管理的事项进行了 审慎核查，核查情况如下： 一、募集资金的基本情况 （一）2021 年首次公开发行股票实际募集资金情况 经中国证券监督管理委员会《关于同意北京诺禾致源科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕737 号）同意，并经上海证券交 易所同意，公司首次公开发行人民币普通股（A 股）4,020 万股，募集资金总额 为人民币 512,952,000.00 元，扣除发行费 ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求（2022 年修订） 》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票 上市规则》《科创板上市公司持续监管办法（试行）》 等有关规定，作为北京诺 禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）首次公开发行股票并 上市的保荐机构，中信证券股份有限公司（以下简称"中信证券"）对诺禾致源首 次公开发行股票部分终止部分募投项目并将剩余募集资金用于新投资项目的情 况进行了核查，具体如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京诺禾致源科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】737 号）同意，公司首次公开发行 人民币普通股 40,200,000.00 股，每股发行价格 12.76 元，共募集资金人民币 512,952,000.00 元，扣除不含税发行费用人民币 63,182,374.86 元，实际募集资金 净额人民币 449,769,625.14 元。上 ...

中信证券股份有限公司 公司境外业务主要采用美元等外币进行结算，因此当汇率出现较大波动时， 汇兑损益将对公司的经营业绩造成一定影响。为有效规避外汇市场的风险，防范 汇率波动对公司经营业绩造成不利影响，提高外汇资金使用效率，合理降低财务 费用，公司拟开展外汇套期保值业务。公司的外汇套期保值业务以正常生产经营 为基础，以规避和防范汇率风险为目的，不进行单纯以盈利为目的的投机和套利 交易。 二、拟开展的套期保值业务概述 （一）开展套期保值业务的目的 公司目前境外收入占比较大，为有效规避外汇市场风险，防范汇率大幅波动 对公司经营业绩造成的不利影响，公司及控股子公司与银行等金融机构开展外汇 套期保值业务，并遵循合法、谨慎、安全和有效原则，不做单纯以盈利为目的的 投机性、套利性的交易操作，所有外汇套期保值业务均以正常业务经营为基础， 以规避和防范汇率风险为目的。 （二）交易金额 根据公司资产规模及业务需求情况，公司拟进行的外汇套期保值业务所需保 1 关于北京诺禾致源科技股份有限公司 开展外汇套期保值业务的核查意见 中信证券股份有限公司（以下简称"中信证券"）作为北京诺禾致源科技股 份有限公司（以下简称"诺禾致源"、"公司" ...

Revenue and Profit - Revenue for the first quarter of 2024 was RMB 468,475,325.62, an increase of 6.32% compared to the same period last year[9] - Net profit attributable to shareholders of the listed company was RMB 27,315,351.75, an increase of 21.40% year-on-year[9] - Total revenue for Q1 2024 reached 468.48 million USD, compared to 440.61 million USD in Q1 2023[36] - Net profit for Q1 2024 was 36.13 million USD, up from 22.99 million USD in Q1 2023[33] - Operating profit for Q1 2024 was 39.63 million USD, up from 23.60 million USD in Q1 2023[33] - Net profit attributable to parent company shareholders increased to 27,315,351.75 from 22,501,126.20[37] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 21,282,735.20, representing a 6.85% increase[47] - Comprehensive income totaled 36.13 million yuan, an increase from 22.99 million yuan in the previous period[80] Assets and Liabilities - Total liabilities as of the first quarter of 2024 amounted to RMB 524,216,301.88, compared to RMB 587,220,292.68 in the previous period[11] - Total owner's equity (or shareholders' equity) was RMB 2,191,580,280.08, slightly down from RMB 2,203,203,300.26 in the previous period[11] - The company's total assets as of the first quarter of 2024 were RMB 2,715,796,581.96, compared to RMB 2,790,423,592.94 in the previous period[11] - Total assets as of March 31, 2024, stood at 3.59 billion USD, slightly down from 3.46 billion USD[35] - Total liabilities increased to 1.12 billion USD from 1.01 billion USD[26] - Total assets decreased by 3.68% to 3,462,237,261.08 compared to the previous year-end[47] - Total current assets decreased to 1,695,916,535.08 from 1,782,868,142.64[44] Cash Flow - Operating cash flow for the first quarter of 2024 was negative RMB 129,709,314.84, compared to negative RMB 37,984,334.67 in the same period last year[24] - Investment cash flow for the first quarter of 2024 was positive RMB 33,106,478.69, a significant improvement from negative RMB 14,788,169.58 in the same period last year[25] - Cash and cash equivalents at the end of the first quarter of 2024 were RMB 249,121,587.45, down from RMB 393,672,815.47 at the beginning of the period[25] - Cash and cash equivalents rose to 704.73 million USD from 481.11 million USD[27] - Net cash flow from financing activities was -51,717,442.10, compared to 15,564,342.24 in the previous period[42] - Cash and cash equivalents at the end of the period stood at 472,019,164.28, down from 691,622,974.60[42] - Monetary funds decreased to 249,221,587.45 from 393,772,815.47[42] - Net cash flow from operating activities was -108,479,469.28, primarily due to increased cash payments for goods and services[47][62] - Net cash flow from operating activities was -108.48 million yuan, a significant decrease from -25.31 million yuan in the previous period[65] - Total cash inflow from operating activities was 401.22 million yuan, compared to 412.42 million yuan in the previous period[65] - Total cash outflow from operating activities was 509.70 million yuan, up from 437.74 million yuan in the previous period[65] - Cash received from investment recovery surged to 733,052,019.16 from 372,532,756.51[41] - Cash outflow for investment activities decreased to 799,232,114.38 from 889,497,929.61[41] Accounts Receivable and Payable - Contract liabilities increased to 754.97 million USD from 703.17 million USD[26] - Accounts receivable decreased to 574.15 million USD from 638.31 million USD[27] - Accounts receivable increased to 448,167,264.65 from 378,711,218.34[42] - Contract liabilities decreased to 325,647,649.04 from 394,961,662.83 in the previous period[44] R&D and Financial Expenses - R&D expenses remained stable at 14.95 million USD in Q1 2024[33] - Financial expenses showed a significant decrease to -3.87 million USD in Q1 2024 from 1.13 million USD in Q1 2023[36] - R&D investment decreased by 2.76% to 22,034,279.90, accounting for 4.70% of operating revenue[47] Earnings Per Share and Return on Equity - Basic earnings per share increased to 0.07 from 0.06[38] - Basic and diluted earnings per share were both 0.07, representing a 16.67% increase[47] - Weighted average return on equity decreased by 0.03 percentage points to 1.11%[47] Shareholder Information - The company's repurchase account held 3,225,051 shares, representing 0.77% of total shares[51] - Li Ruiqiang, the largest shareholder, holds 214,810,148 shares, representing 51.61% of total shares[59] Non-Recurring Items and Other Income - Non-recurring gains and losses amounted to 6.03 million yuan, including 6.35 million yuan from financial asset investment income and fair value changes[68] - Financial assets and liabilities generated a fair value change and disposal gain of 6.35 million yuan[68] - Interest income increased to 1,425,344.88 from 892,773.60, a significant rise[37] - Investment income rose to 6,262,596.32 from 5,340,855.19, showing growth in investment returns[37] - Government subsidies received were 433,708.43 yuan[68] - Tax refunds received were 1.75 million yuan, down from 3.25 million yuan in the previous period[65] - Cash paid for goods and services was 250.93 million yuan, up from 188.57 million yuan in the previous period[65] - Cash paid to employees was 178.63 million yuan, slightly higher than 175.77 million yuan in the previous period[65]

Dividend Distribution and Share Capital - The company plans to distribute a cash dividend of RMB 0.047 per share, totaling RMB 19,409,822.60, representing 10.90% of the net profit attributable to shareholders[6] - The total share capital of the company is 416,200,000 shares, with 3,225,051 shares deducted from the repurchase account[6] - The company did not issue bonus shares or convert capital reserves into share capital in 2023[6] - The company's cash dividend distribution plan is subject to approval at the shareholders' meeting[6] Financial Performance and Metrics - Revenue for 2023 reached RMB 2,002,107,701.39, a year-on-year increase of 3.97%[25] - Net profit attributable to shareholders of the listed company in 2023 was RMB 178,059,764.27, a slight increase of 0.47% compared to the previous year[25] - Revenue from Hong Kong, Macau, Taiwan, and overseas regions in 2023 was RMB 985,364,200, a year-on-year increase of 22.06%[26] - Basic and diluted earnings per share for 2023 remained stable at RMB 0.44 per share[27] - R&D expenditure as a percentage of revenue decreased to 6.20% in 2023, down 0.71 percentage points from the previous year[26] - Total assets at the end of 2023 were RMB 3,594,420,954.11, an increase of 17.92% compared to the end of 2022[25] - Net cash flow from operating activities in 2023 was RMB 334,197,677.56, an increase of 9.96% compared to the previous year[25] - Revenue in the fourth quarter of 2023 was RMB 573,030,207.55, the highest among all quarters[29] - Net profit attributable to shareholders in the fourth quarter of 2023 was RMB 52,785,463.88, also the highest among all quarters[29] - Non-recurring gains and losses in 2023 amounted to RMB 38,072,422.44, an increase from RMB 23,525,546.84 in 2022[31] - Revenue for 2023 reached RMB 20,021.077 million, a year-on-year increase of 3.97%[36] - Net profit attributable to shareholders was RMB 1,780.598 million, up 0.47% year-on-year[36] - R&D investment totaled RMB 1,241.822 million, accounting for 6.20% of revenue[36] - Revenue for the reporting period reached RMB 20,021.08 million, a year-on-year increase of 3.97%[117] - Net profit attributable to shareholders was RMB 1,780.60 million, up 0.47% year-on-year[117] - Operating cash flow increased by 9.95% to RMB 3,341.98 million[117] - R&D investment accounted for 6.20% of revenue, totaling RMB 1,241.82 million[117] - Overseas revenue from Hong Kong, Macau, Taiwan, and other regions grew by 22.06% to RMB 985.36 million[118] - Sales expenses increased by 14.31% due to expanded overseas market efforts[119] - Financial expenses decreased due to higher interest income and reduced exchange losses[120] - Total assets grew by 17.92% to RMB 35,944.21 million[117] - Shareholders' equity increased by 25.07% to RMB 24,574.58 million[117] - Gene sequencing business revenue reached 1,997,501,624.29 RMB, with a gross margin of 42.79%, a decrease of 1.49 percentage points year-over-year[123] - Life science basic research services revenue was 635,638,550.12 RMB, with a gross margin of 55.48%, an increase of 0.75 percentage points year-over-year[123] - Sequencing platform services revenue grew by 14.05% to 952,578,828.46 RMB, with a gross margin increase of 0.06 percentage points[123] - Gene sequencing data production increased by 43.89% to 22,981.84 TB, with sales up 41.38% and inventory up 27.47%[125] - Direct labor costs for gene sequencing services increased by 3.55% to 149,398,580.29 RMB, accounting for 13.07% of total costs[128] - Direct material costs for sequencing platform services rose by 15.25% to 398,816,181.06 RMB, representing 34.90% of total costs[128] - Medical research and technical services saw a 30.25% increase in direct labor costs to 33,907,311.12 RMB[128] - Sales expenses increased by 14.31% to 379,090,796.48 yuan, while R&D expenses decreased by 1.10% to 124,182,171.31 yuan[139] - Operating cash flow increased by 30.25 million yuan due to higher revenue and customer repayments[140] - Investment cash flow increased by 435.52 million yuan due to increased investment in financial assets[140] - Financing cash flow increased by 334.48 million yuan due to A-share stock issuance[140] - Trading financial assets increased by 332.60% to 826.92 million yuan, accounting for 23.01% of total assets[142] - Overseas assets amounted to 1,167.85 million yuan, representing 32.49% of total assets[143] - Novogene (HK) Company Limited reported revenue of 237.81 million yuan and net profit of 1.17 million yuan[145] - Restricted assets totaled 13.11 million yuan, primarily due to performance bonds and deposits[146] - Total investment in 2023 was RMB 12,732,072.02, a decrease of 49.99% compared to the previous year's RMB 25,457,831.75[149] - The company invested USD 222,042 in May 2023, USD 229,698 in August 2023, and USD 114,849 in December 2023 in the Illumina fund[149] - Invested RMB 3,000,000 in Suzhou Jinsha Lake Runpu Venture Capital Partnership in August 2023[149] - Invested SGD 1,087,800 in NOVOGENE N HEALTH (THAILAND) COMPANY LIMITED in July 2023, classified as a long-term equity investment[150] - Held RMB 150 million in transferable large-denomination certificates of deposit as of December 31, 2023, with accrued interest of RMB 9,052,693.33[151] - The fair value of bank wealth management products at the end of the period was RMB 826,916,983.34[154] - The fair value of other equity instrument investments at the end of the period was RMB 32,344,900.00[154] - The fair value of other non-current financial assets at the end of the period was RMB 157,420,507.07[154] - Total fair value of financial assets at the end of the period was RMB 1,017,753,110.41[154] - The company's subsidiary, Tianjin Novogene Bioinformatics Technology Co., Ltd., reported a net loss of RMB 3,045,140 in 2023[158] Market and Industry Trends - Global gene sequencing market is projected to grow from USD 13.518 billion in 2020 to USD 37.721 billion by 2026, with a CAGR of 19.1%[36] - The global gene sequencing market size reached $13.518 billion in 2020 and is expected to grow to $37.721 billion by 2026, with a CAGR of 19.1% from 2021 to 2026[166] - The gene sequencing services market accounted for 51.74% of the total industry in 2020, with a market size of $6.994 billion, and is projected to reach $21.066 billion by 2026, with a CAGR of 20.7%[166] - China's gene sequencing market size reached $1.339 billion in 2020 and is expected to grow to $4.235 billion by 2026, with a CAGR of 21.6%, higher than the global market growth rate[166] - The gene sequencing industry is divided into upstream (sequencing equipment and reagent manufacturers), midstream (sequencing service providers), and downstream (end-users including universities, research institutions, and individuals)[167][168][170] - Major upstream players include Illumina, Thermo Fisher, MGI (BGI Genomics), Pacific Biosciences, and Oxford Nanopore Technologies, with high market concentration due to the dominance of high-throughput sequencing technology[167] - Midstream service providers are categorized into two types: those serving basic research (e.g., Novogene, Biomarker) and those focusing on clinical applications (e.g., Burning Rock, Genetron Health)[168] - The company entered the upstream high-throughput sequencing equipment and reagent manufacturing field in 2013 through the acquisition of Complete Genomics and has since launched a series of localized sequencing instruments and reagent products[167] - The development of gene sequencing technology has gone through three stages: Sanger sequencing (high accuracy but low throughput), high-throughput sequencing (mainstream technology with high accuracy and throughput), and single-molecule sequencing (long read length but lower accuracy)[165] - The integration of genomics, proteomics, and metabolomics technologies, combined with bioinformatics analysis capabilities, enables the company to provide comprehensive solutions for scientific research[169] - The company's midstream services focus on reducing sequencing costs, shortening sequencing cycles, and lowering the threshold for gene sequencing applications, driving the widespread adoption of sequencing technology in both basic research and commercial applications[169] - Second-generation sequencing technology will remain the mainstream for a long time due to its high throughput, accuracy, and relatively low cost[171] - Multi-omics research technology is a key future tool for life sciences and medical research, integrating genomics, transcriptomics, proteomics, and metabolomics[172] - The gene sequencing service industry is moving towards centralized outsourcing, with large service providers increasing their market share[172] - The clinical application of gene sequencing is rapidly growing, particularly in NIPT, genetic disease diagnosis, and tumor diagnosis and treatment[173] Corporate Governance and Compliance - The company has no significant risks affecting its operations during the reporting period[4] - The company's financial report was audited by Ernst & Young (Special General Partnership) with a standard unqualified opinion[5] - The company's future plans and strategies are forward-looking statements and do not constitute a commitment to investors[8] - The company has no non-operational fund occupation by controlling shareholders or related parties[9] - The company has no violations of decision-making procedures for external guarantees[9] - The company's board of directors unanimously approved the annual report, ensuring its authenticity, accuracy, and completeness[4] - The company strictly adheres to the requirements of the "Company Law," "Securities Law," and other relevant laws and regulations, continuously improving its corporate governance structure and internal management and control systems[183] - The company ensures that all shareholders, especially minority shareholders, can fully exercise their voting rights by combining on-site and online voting methods during shareholder meetings[183] - The company has established four specialized committees under the board of directors—strategy, audit, compensation and evaluation, and nomination—to provide scientific decision-making support[184] Research and Development - The company utilizes advanced sequencing technologies such as Ribo-seq, ATAC-seq, and ChIP-seq for genomic research[16][17] - The company is involved in non-invasive prenatal testing (NIPT) through the analysis of cell-free RNA (cfRNA) in maternal blood[17] - The company employs cutting-edge techniques like CUT&Tag for studying DNA-protein interactions[17] - The company opened new laboratories in Munich, Germany, and Japan, enhancing its global localization strategy[37] - The company developed a multi-omics integrated analysis platform, offering unified analysis services for various omics data[37] - The company launched an automated mass spectrometry multi-omics sample pre-processing system, integrating 17 precision devices for 24/7 intelligent production[40] - The company expanded its clinical application of gene sequencing, with its mutation detection kit being adopted by dozens of core hospitals[40] - The company strengthened its NGS technology application in genetic diseases, collaborating with over 10 top-tier hospitals and hundreds of third-party medical institutions[41] - The company's independently developed pathogen metagenomic high-throughput detection product (mNGS) PD-seq series has successfully established research collaborations with several top-tier hospitals[42] - The company's "Automated Sample Preparation System" (Model: NovoEMD LPS-32) was officially approved by the Tianjin Medical Products Administration on April 10, 2023, achieving automation in NGS library preparation[42] - The company has established a globally leading gene sequencing platform with a large throughput scale, and has published or been mentioned in a total of 22,852 SCI articles by 2023, with a cumulative impact factor of nearly 148,277.93[43] - The company holds 66 invention patents and 356 software copyrights[43] - The company has built a global technical service network, covering approximately 90 countries and regions across six continents, and serves nearly 7,300 customers[44] - The company's third-class medical device "Human EGFR, KRAS, BRAF, PIK3CA, ALK, ROS1 Gene Mutation Detection Kit (Semiconductor Sequencing Method)" was approved in August 2018, becoming one of the first NGS-based tumor gene detection kits approved in China[44] - The company's products include life science basic research services, medical research and technical services, and library construction and sequencing platform services[45] - The company has developed an automated extraction process for relatively standardized samples and has accumulated over a hundred personalized extraction methods for non-standard samples[51] - The company has achieved automation in standard library construction and has rich experience in differential processing of non-standard library construction processes[51] - The company focuses on improving automation levels at each stage to reduce manual errors and improve sequencing efficiency and quality stability[52] - The company actively promotes digital marketing through online channels to enhance product awareness and customer interaction[53] - The company provides full-process, one-on-one professional services to establish long-term customer relationships[54] - The company has a high-quality technical and management team of over 1,000 experts and talents in fields such as molecular biology, medicine, clinical laboratory science, mathematics, physics, agronomy, computer science, and informatics[61] - The company has co-authored or been mentioned in 22,852 SCI articles with a cumulative impact factor of nearly 148,277.93, and holds 66 invention patents and 356 software copyrights[61] - The company serves nearly 7,300 customers globally, including 4,200 research institutes and universities, 680 hospitals, and 2,400 pharmaceutical and agricultural enterprises, covering approximately 90 countries and regions across six continents[61] - The company established a local laboratory in Germany in 2023 and plans to establish another in Japan in early 2024, with further plans to build and expand laboratories in more regions to better serve clients[62] - The company has developed a comprehensive multi-omics service system, including genomics, variantomics, transcriptomics, epigenomics, microbiomics, spatial transcriptomics, single-cell sequencing, mass spectrometry, and genotyping technologies[62] - The company has served global clients in publishing over 210 single-cell related research papers by 2023, offering a full range of single-cell sequencing services including tissue sample dissociation, cell sorting, microfluidic droplet-based single-cell capture, and micro-well-based single-cell capture[63] - The company has achieved DNA extraction success rates of 96.71%, RNA extraction success rates of 89.37%, and third-generation extraction success rates of 91.30% through optimized extraction methods for various sample types[67] - The company has introduced multiple Illumina NovaSeq X Plus, BGI DNBSEQ-T7, and PacBio Revio sequencing platforms, significantly enhancing sequencing throughput and global delivery capabilities[69] - The company has established a high-performance data center with approximately 92TB of memory, 22.5PB of local storage, and scalable cloud storage up to 100PB, supporting big data analysis and storage needs[69] - The company has developed 320 software copyrights in bioinformatics, providing standardized and efficient bioinformatics analysis solutions for life science researchers[69] - The company has conducted over 130 lean improvement activities globally, enhancing efficiency across various stages from sample collection to sequencing[70] - The company deployed the Falcon II system in key laboratories worldwide, including the UK, US, Tianjin, Guangzhou, and Shanghai, achieving intelligent upgrades in global delivery systems[71] - The company has developed 19 patents and over 40 software copyrights in de novo sequencing technology, with 120 co-authored papers published in international journals, accumulating an impact factor of over 1,225[72] - The company launched the NGP (Novogene Germplasm resource screening panel) and developed over ten commercialized liquid chip products for agricultural breeding, enabling efficient and low-cost molecular breeding[73] - The company upgraded its molecular breeding framework, including a breeding value prediction system with nine models and a precision variety identification architecture with five machine learning algorithms[74] - The company holds 5 patents and 52 software copyrights in transcriptomics and epigenomics sequencing, with 15 papers published in international journals, including top-tier journals like *The Plant Cell*[75] - The company achieved breakthroughs in ATAC-seq for challenging species and optimized Hi-C library construction, improving sequencing data efficiency to advanced levels[76] - The company obtained 4 patents and over 20 software copyrights in metagenomics sequencing, with 13 papers published in international journals[77] - Introduced more accurate alignment algorithms and scoring models, significantly improving metagenomic data assembly efficiency and alignment quality[78] - Served global customers with over 210 single-cell related research papers published by 2023[78] - Increased the success rate of processing frozen tissue samples to over 90%, expanding the application range of single-cell sequencing technology[79] - Completed over 10,000 single-cell sample sequencing cases in the past 5 years[79] - Established FFPE sample processing technology, enabling single-cell and spatial multi-omics integrated analysis of pathological samples[79] - Developed automated cell annotation tools, significantly improving the efficiency of single-cell data analysis[80] - Obtained 2 invention patents and 21 software copyrights in single-cell sequencing data analysis by 2023[80] - Developed a multi-omics database management platform to assist users in managing massive multi-omics data[81] - Constructed the world's first graphical pan-genome for a forage crop, Pennisetum, in collaboration with Sichuan Agricultural University[82] - Developed a 16s microbial classification unit abundance and host